InvestorsHub Logo
Followers 51
Posts 9208
Boards Moderated 1
Alias Born 10/25/2007

Re: None

Monday, 12/18/2023 11:33:11 PM

Monday, December 18, 2023 11:33:11 PM

Post# of 13602
A personalized approach to treating cancer
Considering the candidate's progress in clinical trials and Moderna's additional work to prepare it for regulatory review, mRNA-4157 could become another near- to medium-term launch. The product may stand out because it's designed to specifically attack each patient's tumor type. So far, this personalized approach is clearly producing positive results; if this continues, the eventual product could be a game changer in the world of oncology.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRNA News